Fri Sep 20 14:07:51 UTC 2024: ## E Fund Management Reduces Stake in Sana Biotechnology, While Other Investors Show Interest

**New York, NY (Sept. 20, 2024)** – E Fund Management Co. Ltd. trimmed its position in Sana Biotechnology, Inc. (NASDAQ: SANA) by 11.5% during the second quarter, according to a recent SEC filing. The institutional investor now owns 20,675 shares, valued at $113,000.

Despite E Fund’s reduction, other investors are showing increasing interest in Sana Biotechnology, a company focused on developing cell-based therapies for various diseases.

Victory Capital Management Inc. and Hartline Investment Corp. both acquired new positions in Sana Biotechnology during recent quarters. Zurcher Kantonalbank Zurich Cantonalbank expanded its holdings by 20.6%, while Arizona State Retirement System increased its stake by 36.7%. ProShare Advisors LLC also raised its position by 14.8%.

Overall, 88.23% of Sana Biotechnology’s stock is owned by hedge funds and other institutional investors, indicating significant institutional interest in the company’s potential.

Sana Biotechnology’s stock opened at $4.62 on Friday, with a 50-day moving average of $5.44 and a 200-day moving average of $7.12. The company’s stock has traded between a one-year low of $2.74 and a one-year high of $12.00.

Analysts are also optimistic about Sana Biotechnology’s prospects. HC Wainwright maintained a “buy” rating with a lowered price target of $11.00, while Citigroup raised its price target to $15.00 and also assigned a “buy” rating. Rodman & Renshaw initiated coverage with a “buy” rating and a $16.00 price target.

This news follows E Fund Management Co. Ltd’s recent investments in American Express (NYSE: AXP) and Relay Therapeutics, Inc. (NASDAQ: RLAY).

**About Sana Biotechnology:**

Sana Biotechnology, Inc. is a leading biotechnology company dedicated to developing innovative cell-based therapies for a wide range of diseases, including cancer, diabetes, and neurological disorders. The company’s platform leverages advanced cell engineering techniques to create powerful new treatments with the potential to transform patient lives.

Read More